Form D · Biotechnology
RaNA Therapeutics, Inc.
Cambridge, MA · CIK 0001535803
Offering snapshot reported Nov 30, 2011 · SEC filing
- Reported sold
- $2.67M Offering amount: $20.7M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 16, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 30, 2011 | Initial | $2,665,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-169407
Source: Form D, filed Nov 30, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mitchell S. Bloom | Executive |
| Jean Francois Formela | Director |
| Brian Gallagher | Director |
| Arthur M. Krieg | Director, Executive |
| Ankit Mahadevia | Director |
| Steve Padgette | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
25 First Street, Suite 303
Cambridge, MA, 02141
Cambridge, MA, 02141